NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ZITUVIMET XR (sitagliptin and metformin hydrochloride) by Aurobindo Pharma is dipeptidyl peptidase 4 inhibitors [moa]. First approved in 2024.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIMET XR is a fixed-dose combination of sitagliptin (a DPP-4 inhibitor) and metformin hydrochloride in extended-release formulation for oral administration. It is indicated for type 2 diabetes mellitus management by enhancing incretin-mediated glucose control and improving insulin secretion. This combination leverages complementary mechanisms: sitagliptin increases GLP-1 and GIP levels, while metformin reduces hepatic glucose production.
Growth
Recently approved in early growth phase with moderate competitive pressure (30% intensity), indicating active market positioning and expanding commercial infrastructure needs.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Career Relevance
Working on ZITUVIMET XR offers exposure to launch-phase commercial execution and competitive positioning in the high-volume type 2 diabetes segment. Early-career professionals can build portfolio management and go-to-market expertise during the growth phase before market maturation.
Brand Manager
Worked on ZITUVIMET XR at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.